Experimental Pancreatic Cancer Vaccine Shows Promising Early Results in Human Trial

A groundbreaking experimental vaccine aimed at preventing pancreatic cancer has yielded encouraging results in its initial human trial. Scientists at Johns Hopkins School of Medicine in the U.S. reported that none of the high-risk participants developed pancreatic cancer during the monitoring period, offering a glimmer of hope against one of the deadliest forms of the disease.

The Phase I study, published in the journal Cancer Discovery, involved 20 individuals genetically predisposed to pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive type of pancreatic cancer. These participants had precancerous pancreatic cysts but had not yet been diagnosed with cancer. They received four doses of the vaccine, named mKRAS-VAX, over five weeks, followed by a booster shot.

The vaccine is designed to target six frequent mutations in the KRAS gene, which is implicated in over 90% of pancreatic cancer cases. The research found that 18 out of the 20 participants (90%) mounted a significant immune response against these KRAS mutations. The immune system activity increased substantially, and half of the volunteers developed an immune response targeting all six intended mutations. The vaccine also stimulated the production of T-cells, crucial for fighting abnormal cells and providing long-term immune memory.

During an average follow-up of 16.5 months, no participant developed pancreatic cancer. Notably, about 37.5% of vaccinated individuals experienced a reduction or disappearance of their precancerous pancreatic cysts. While the study's primary goal was to assess the vaccine's safety, researchers are optimistic about its potential. Dr. Neeha Zaidi highlighted it as the "first proof-of-concept" for using vaccines to prevent pancreatic cancer in humans. Professor Michael G. Goggins suggested the vaccine might help stabilize or even shrink pancreatic cysts, though he stressed the need for larger trials to confirm these findings.

Despite the promising early outcomes, the researchers acknowledge the study's limitations, including the small number of participants and its design not being intended to measure clinical effectiveness. If future, larger-scale studies confirm these results, this vaccine could pave the way for a new approach in preventing pancreatic cancer.

“

This study represents the first proof-of-concept for the use of vaccines to prevent pancreatic cancer in humans.